Brad Spellberg

33.0k total citations · 10 hit papers
216 papers, 21.6k citations indexed

About

Brad Spellberg is a scholar working on Infectious Diseases, Epidemiology and Molecular Medicine. According to data from OpenAlex, Brad Spellberg has authored 216 papers receiving a total of 21.6k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Infectious Diseases, 88 papers in Epidemiology and 54 papers in Molecular Medicine. Recurrent topics in Brad Spellberg's work include Antifungal resistance and susceptibility (60 papers), Antibiotic Resistance in Bacteria (54 papers) and Fungal Infections and Studies (44 papers). Brad Spellberg is often cited by papers focused on Antifungal resistance and susceptibility (60 papers), Antibiotic Resistance in Bacteria (54 papers) and Fungal Infections and Studies (44 papers). Brad Spellberg collaborates with scholars based in United States, Canada and Greece. Brad Spellberg's co-authors include John E. Edwards, Ashraf S. Ibrahim, David N. Gilbert, John S. Bradley, Helen W. Boucher, George H. Talbot, John Bartlett, John G. Bartlett, Michael Scheld and Louis B. Rice and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Investigation.

In The Last Decade

Brad Spellberg

208 papers receiving 20.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

2008 3.9k citations John E. Edwards, Brad Spellberg et al. Clinical Infectious Diseases profile →
The Epidemic of Antibiotic-Resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of America

2007 1.3k citations Brad Spellberg, John E. Edwards et al. Clinical Infectious Diseases profile →
Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management

2005 991 citations Brad Spellberg, John E. Edwards et al. profile →
Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges

2017 828 citations Travis B. Nielsen, Robert A. Bonomo et al. profile →
Necrotizing Fasciitis Caused by Community-Associated Methicillin-ResistantStaphylococcus aureusin Los Angeles

2005 760 citations Arnold S. Bayer, Brad Spellberg et al. profile →
Type 1/Type 2 Immunity in Infectious Diseases

2001 673 citations Brad Spellberg, John E. Edwards Clinical Infectious Diseases profile →
Trends in Antimicrobial Drug Development: Implications for the Future

2004 633 citations Brad Spellberg, Eric P. Brass et al. Clinical Infectious Diseases profile →
Nosocomial fungal infections: epidemiology, diagnosis, and treatment

2007 565 citations Brad Spellberg et al. profile →
Pathogenesis of Mucormycosis

2012 508 citations Ashraf S. Ibrahim, Brad Spellberg et al. Clinical Infectious Diseases profile →
The Future of Antibiotics and Resistance

2013 463 citations Brad Spellberg et al. profile →

Peers

Countries citing papers authored by Brad Spellberg

Since Specialization

Citations

This map shows the geographic impact of Brad Spellberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brad Spellberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brad Spellberg more than expected).

Fields of papers citing papers by Brad Spellberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brad Spellberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brad Spellberg. The network helps show where Brad Spellberg may publish in the future.

Co-authorship network of co-authors of Brad Spellberg

This figure shows the co-authorship network connecting the top 25 collaborators of Brad Spellberg. A scholar is included among the top collaborators of Brad Spellberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brad Spellberg. Brad Spellberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Population pharmacokinetics and humanized dosage regimens matching the peak, area, trough, and range of amikacin plasma concentrations in immune-competent murine bloodstream and lung infection models 2024 ·Antimicrobial Agents and Chemotherapy ·Yuanyuan Jiao, Jun Yan, Dhruvitkumar S. Sutaria, (unknown), Michael Vicchiarelli, (unknown), (unknown), (unknown), (unknown), Nirav R. Shah, Brad Spellberg, Robert A. Bonomo, George L. Drusano, Arnold Louie, Brian Luna, Jürgen B. Bulitta	0
2	Individual Components of Polymyxin B Modeled via Population Pharmacokinetics to Design Humanized Dosage Regimens for a Bloodstream and Lung Infection Model in Immune-Competent Mice 2023 ·Antimicrobial Agents and Chemotherapy ·Yuanyuan Jiao, Jun Yan, Michael Vicchiarelli, Dhruvitkumar S. Sutaria, (unknown), (unknown), Brad Spellberg, Robert A. Bonomo, George L. Drusano, Arnold Louie, Brian Luna, Jürgen B. Bulitta	5
3	Real-World Application of Oral Therapy for Infective Endocarditis: A Multicenter, Retrospective, Cohort Study 2023 ·Clinical Infectious Diseases ·(unknown), Noah Wald‐Dickler, (unknown), Catherine P. Canamar, (unknown), (unknown), Kusha Davar, Fernándo Domínguez, (unknown), (unknown), (unknown), (unknown), Emi Minejima, (unknown), (unknown), Rachel Baden, Paul Holtom, Brad Spellberg	33
4	Capsule carbohydrate structure determines virulence in Acinetobacter baumannii 2021 ·PLoS Pathogens ·(unknown), Travis B. Nielsen, Jun Yan, Ulrike MacDonald, Gisela Di Venanzio, Somnath Chakravorty, (unknown), Mario F. Feldman, Thomas A. Russo, Evgeny Vinogradov, Brian Luna, Meredith S. Wright, Mark D. Adams, Brad Spellberg	72
5	Monoclonal Antibody Therapy against Acinetobacter baumannii 2021 ·Infection and Immunity ·Travis B. Nielsen, Jun Yan, (unknown), (unknown), Rachel Li, Juan José Nogal‐Ruiz, (unknown), (unknown), (unknown), Peter Oelschlaeger, Kyle Hurth, (unknown), Brian Luna, Robert A. Bonomo, Brad Spellberg	28
6	2-Mercaptomethyl Thiazolidines (MMTZs) Inhibit All Metallo-β-Lactamase Classes by Maintaining a Conserved Binding Mode 2021 ·ACS Infectious Diseases ·Philip Hinchliffe, Diego M. Moreno, (unknown), María F. Mojica, V. Rodríguez Martínez, (unknown), Brad Spellberg, George L. Drusano, Claudia Banchio, Graciela Mahler, Robert A. Bonomo, Alejandro J. Vila, James Spencer	15
7	Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes 2019 ·Clinical Infectious Diseases ·Emi Minejima, (unknown), (unknown), Melissa Mert, Wendy J. Mack, Rosemary C. She, Paul Nieberg, Brad Spellberg, Annie Wong‐Beringer	97
8	Adjunctive Corticosteroid Therapy in the Treatment of Coccidioidal Meningitis 2017 ·Clinical Infectious Diseases ·George R. Thompson, Janis E. Blair, (unknown), (unknown), Michael Bolaris, (unknown), Rodrigo López, Arash Heidari, Antonino Catanzaro, José Cadena, Peter Chin‐Hong, Brad Spellberg, Royce H. Johnson	15
9	Diabetes Exacerbates Infection via Hyperinflammation by Signaling through TLR4 and RAGE 2017 ·mBio ·Travis B. Nielsen, Paul Pantapalangkoor, Jun Yan, Brian Luna, (unknown), Kevin W. Bruhn, Brandon Tan, (unknown), Robert A. Bonomo, Ann Marie Schmidt, Michael P. Everson, Frederick P. Duncanson, Terence M. Doherty, Lin Lin, Brad Spellberg	48
10	Acinetobacter baumannii virulence requires LPS activation of TLR4 (55.12) 2012 ·The Journal of Immunology ·Lin Lin, Brandon Tan, Beverlie Baquir, Tiffany Ho, Paul Pantapalangkoor, Brad Spellberg	1
11	The Deferasirox–AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial 2011 ·Journal of Antimicrobial Chemotherapy ·Brad Spellberg, Ashraf S. Ibrahim, Peter Chin‐Hong, Dimitrios P. Kontoyiannis, Michele I. Morris, John R. Perfect, David N. Fredricks, Eric P. Brass	219
12	The OmpA vaccine protects mice against lethal, extreme drug resistant- Acinetobacter baumannii infection (106.20) 2011 ·The Journal of Immunology ·Guanpingsheng Luo, Lin Lin, Ashraf S. Ibrahim, Brad Spellberg	1
13	Safety and Outcomes of Open-Label Deferasirox Iron Chelation Therapy for Mucormycosis 2009 ·Antimicrobial Agents and Chemotherapy ·Brad Spellberg, David R. Andes, (unknown), Anne M. Anglim, Hector Bonilla, Glenn E. Mathisen, Thomas J. Walsh, Ashraf S. Ibrahim	72
14	The Antifungal Vaccine Derived from the Recombinant N Terminus of Als3p Protects Mice against the Bacterium Staphylococcus aureus 2008 ·Infection and Immunity ·Brad Spellberg, Ashraf S. Ibrahim, Michael R. Yeaman, Lin Lin, Yue Fu, Valentina Avanesian, Arnold S. Bayer, Scott G. Filler, Peter N. Lipke, Henry N. Otoo, John E. Edwards	123
15	Posaconazole Mono- or Combination Therapy for Treatment of Murine Zygomycosis 2008 ·Antimicrobial Agents and Chemotherapy ·Ashraf S. Ibrahim, Teclegiorgis Gebremariam, Julie Schwartz, John E. Edwards, Brad Spellberg	83
16	Phagocytes are Crucial End-Effectors of rAls3p-n Vaccine-Induced Protection Against Murine Disseminated Candidiasis 2008 ·46th Annual Meeting ·Brad Spellberg	1
17	Safety and Outcomes of Deferasirox Iron Chelation Therapy for Mucormycosis 2008 ·46th Annual Meeting ·Brad Spellberg	3
18	The Anti- Candida Vaccine Based on the Recombinant N-Terminal Domain of Als1p Is Broadly Active against Disseminated Candidiasis 2006 ·Infection and Immunity ·Ashraf S. Ibrahim, Brad Spellberg, Valentina Avanesian, Yue Fu, John E. Edwards	58
19	Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6 2004 ·Journal of Antimicrobial Chemotherapy ·Brad Spellberg, (unknown), Arnold S. Bayer	69
20	Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy. 1997 ·Journal of Clinical Investigation ·Daniel H. Libraty, (unknown), Koichi Uyemura, D. Jullien, Brad Spellberg, Thomas H. Rea, Robert L. Modlin	78

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact